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Available online xxxxBackground:Among heart failure patients diagnosed as having exertional oscillatory ventilation (OV), some pres-
ent with OV at rest that persists during exercise, and others develop OV only after the onset of exercise during
cardiopulmonary exercise (CPX) testing. We tested whether or not there was any difference in the prognostic
significance between the two abnormal breathing patterns.
Methods: Patients with New York Heart Association class III-heart failure were categorized into the following 3
groups according to their ventilation pattern during the CPX: patients with an OV pattern at rest that persisted
for ≥60% of the exercise test at an amplitude of ≥15% of the average resting value (group 1), patients with the
same abnormal ventilatory pattern as group 1 that was observed only during exercise (group 2), and patients
without any OV (group 3). The patients were followed-up for at least 2 years to assess the composite outcome
of cardiac death or hospitalization for worsening heart failure.
Results: The occurrence of the composite outcome differed significantly across the groups with its highest occur-
rence in group 1 (21/29 [72.4%], 15/38 [39.5%] and 48/167 [28.7%]; log-rank P b 0.001). In multivariate hazard
analyses, an N-terminal pro-brain natriuretic peptide of N900 pg/mL (hazard ratio [HR] = 1.72, P = 0.04), and
group 1 (HR 2.03, P = 0.02) were independently associated with the composite outcome.
Conclusions: Checking for the resting OV prior to incremental exercise during CPX testing may be helpful in risk-
stratification among subjects with advanced heart failure.
© 2018 Elsevier B.V. All rights reserved.Keywords:
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Exertional oscillatory ventilation (EOV) is an abnormal ventilatory
response to exercise, and is characterized by cyclic fluctuations in
minute ventilation during incremental exercise [1]. EOV is recognized
as reflecting advanced disease severity and a poor prognosis in patients
with heart failure [2,3]. Despite its prognostic significance, there is
currently no gold standard definition of the EOV, and therefore, a wideardiovascular Center, Onomichi
Japan.
eliability and freedom from bias
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nal of Cardiology, https://doivariety of EOV patterns have been reported [4–6]. The newest scientific
statement from the American Heart Association [2,3] recommends the
following EOV definition: an oscillatory pattern at rest that persists for
≥60% of the exercise test at an amplitude of ≥15% of the average resting
value. Importantly, this definition indicates that the OV must be
observed at rest before starting the exercise as well as during the
exercise. Nevertheless, in the majority of the studies on EOV, no resting
phase prior to the warm-up has been included in the cardiopulmonary
exercise (CPX) protocol or has been mentioned, if any [4]. Probably
because of that, in a considerable number of the studies, if the OV was
observed during exercise, it was considered the EOV regardless of
whether or not any resting OV was confirmed. In fact, even
representative images of the EOV in some articles [1,6–8] have shown
a phenomenon in which the OV is never observed during the restingognostic significance of oscillatory ventilation at rest in patients with
.org/10.1016/j.ijcard.2019.11.098
2 H. Kinoshita et al. / International Journal of Cardiology xxx (xxxx) xxxphase, however, it emerges shortly after the onset of exercise. Therefore,
it is safely said that this OV pattern is not uncommon in clinical practice.
The goal of the present studywas to test the hypothesis that theOV seen
both at rest and during exercise would have a different prognostic
significance as compared to theOV seen only during exercise in patients
with advanced heart failure.2. Methods
2.1. Study population
This study was designed as a prospective observational study.
Patients were recruited in Hiroshima University Hospital and
Onomichi General Hospital from January 2013 to December 2014.
Patients were eligible for inclusion if they were on a stable medical
therapy for New York Heart Association (NYHA) class III heart
failure. Patients were excluded from consideration if they were
unable to exercise or had experienced a major cardiovascular event
in the previous 6 weeks [9]. Eligible patients were enrolled after giv-
ing informed consent. All patients underwent laboratory testing and
an echocardiogram with the standard measurements [10,11] after
the inclusion. The study protocol was approved by the research com-
mittee of each institution.2.2. CPX procedure
A symptom-limited CPX was performed on an electromagneti-
cally braked cycle ergometer (Aerobike 75XLIII; Combi Wellness
Co., Ltd., Tokyo, Japan) with the use of a conservative ramp protocol.
The exercise test was initiated with a 3-minute rest on the ergometer
followed by a 3-minute warm-up at 10W, 50 rpm. Thework rate was
then increased incrementally by 1 W every 6 s. The test termination
criteria consisted of symptoms such as dyspnea or fatigue, ventricu-
lar tachycardia, a horizontal or downsloping ST-segment depression
of ≥2 mm, or a drop in the systolic blood pressure of ≥20 mmHg [12].
During the exercise test, a 12-lead electrocardiogram and pulse
oximeter were continuously monitored, and the blood pressure
was manually measured every minute. The breath-by-breath minute
ventilation (VE), carbon dioxide production (VCO2), and oxygen
consumption (VO2) were measured with the use of a metabolic
cart (AE310; Minato Medical Science Co., Ltd., Osaka, Japan). The fol-
lowing 3 valuables were reported [2]. The peak VO2was calculated as
the highest consecutive 30-second averaged value during the last
minute of exercise or early recovery. The VE/VCO2 slope was ob-
tained by a linear regression analysis of the data acquired through-
out the entire period of exercise. The respiratory exchange ratio
was defined as the VCO2/VO2 ratio, and its peak value was reported.Fig. 1. Representative example of the ventilatory pattern during the cardiopulmonary
exercise (CPX) testing in each patient group. The oscillatory ventilation (OV) was
observed both during the resting phase and incremental exercise in a group 1 patient
(panel A). The OV was not seen at rest, however, it emerged after the start of pedaling
in a subject in group 2 (panel B). The OV was not noted throughout the CPX protocol in
a group 3 patient (panel C).2.3. Oscillatory ventilation and patient grouping
The term OV has been used as a synonym of periodic breathing
defined as cyclic waxing and waning of the tidal volume without
apnea [13]. The most recent scientific statement [2,3] defined EOV
as an OV pattern at rest that persists for ≥60% of the exercise test at
an amplitude of ≥15% of the average resting value. The subjects
were categorized into the following 3 groups according to the
breathing pattern during the CPX: patients with the scientific
statement-defined EOV (i.e. OV observed at rest as well as during ex-
ercise; group 1, Fig. 1A), patients in whom the same abnormal venti-
latory pattern as in group 1 was observed only during warm-up or
incremental exercise and was never noted during the resting phase
(group 2, Fig. 1B), and patients without any OV (group 3, Fig. 1C).
OV was visually determined by 2 experienced cardiologists.Please cite this article as: H. Kinoshita, A. Sairaku, N. Morishima, et al., Pr
advanced heart failure u..., International Journal of Cardiology, https://doi2.4. Outcome measure
The primary endpoint was a composite of cardiac death and hospi-
talization for worsening heart failure.
Cardiac death included any death due to a proximate cardiac cause
(e.g., myocardial infarction, heart failure, or fatal arrhythmia),ognostic significance of oscillatory ventilation at rest in patients with
.org/10.1016/j.ijcard.2019.11.098
Table 1
Baseline characteristics of the study subjects (N = 234).
Group 1 Group 2 Group 3 P-value
N = 29 N = 38 N = 167
Age (years) 65.3 ± 12.9 68 ± 10.7 68.7 ± 11.7 0.35
Male 19 (65.5) 26 (68.4) 89 (53.3) 0.15
Body mass index (kg/m2) 23.2 ± 4.1 24.2 ± 4.8 23.1 ± 4.3 0.35
Ischemic etiology 6 (20.7) 13 (34.2) 63 (37.7) 0.21
Valvular insufficiency 8 (27.6) 9 (23.7) 49 (29.3) 0.78
Medical history
Hypertension 20 (69) 33 (86.8) 117 (70.1) 0.1
Diabetes mellitus 8 (27.6) 15 (39.5) 58 (34.7) 0.6
Dyslipidemia 10 (34.5) 24 (63.2) 91 (54.5) 0.06
Myocardial infarction 6 (21.4) 13 (34.2) 49 (29.3) 0.53
Peripheral vascular disease 0 2 (5.3) 5 (3) 0.47
Atrial fibrillation 10 (34.5) 5 (13.2) 24 (14.4) 0.02
Chronic obstructive
pulmonary disease
5 (17.2) 5 (13.2) 11 (6.6) 0.11
Echocardiographic
parameters
Left ventricular ejection
fraction (%)
40.2 ± 14.3 48 ± 14.1 54.3 ± 13.5 b0.001
Left ventricular
end-systolic volume
(mL/m2)
62.8 ± 42.1 38 ± 23.8 32.1 ± 25.5 b0.001
Average E/e′ ratio 17.8 ± 10.3 18.7 ± 9.4 15.9 ± 7.8 0.15
Laboratory data
Hemoglobin (g/dL) 12.4 ± 2.3 13.2 ± 2.2 12.4 ± 1.7 0.04
eGFR (mL/min/1.73 m2) 52.1 ± 19.3 50.4 ± 22.6 56.5 ± 21.7 0.22
NT pro-BNP (pg/mL) 1749
[898.5–3054]
806
[485–2035]
715
[375–1636]
0.003
Medical therapy
ACE-I or ARB 23 (79.3) 28 (73.7) 119 (71.3) 0.66
Diuretic 25 (86.2) 31 (81.6) 123 (73.7) 0.24
β-Blocker 0.29
β1–β2 unselective
blocker
20 (69) 20 (52.6) 97 (58.1)
β1 selective blocker 7 (24.1) 11 (29) 33 (19.8)
None 2 (6.9) 7 (18.4) 37 (22.2)
Cardiopulmonary exercise
testing parameters
Peak respiratory exchange
ratio
1.16 ± 0.16 1.13 ± 0.14 1.16 ± 0.13 0.43
Peak VO2 (mL/min/kg) 11.6 ± 2.9 11.9 ± 3.1 13.4 ± 3.4 0.004
VE/VCO2 slope 35.1 ± 5 37.6 ± 11.1 32.9 ± 8 0.006
The values are themeans±SDs, n (%), ormedian [interquartile range] as appropriate. Val-
vular insufficiency includes moderate or severe aortic or mitral valve insufficiencies. E/e′
= peak early mitral inflow velocity / early diastolic mitral annulus velocity, eGFR = esti-
mated glomerular filtration rate, NT pro-BNP= N-terminal pro-brain natriuretic peptide,
ACE-I = angiotensin converting enzyme inhibitor, ARB= angiotensin II receptor blocker,
VO2=oxygen consumption, VE=minute ventilation, VCO2=carbondioxide production.
3H. Kinoshita et al. / International Journal of Cardiology xxx (xxxx) xxxunwitnessed death or death of unknown cause, and all cardiac
procedure-related deaths [14,15]. Patients were followed-up for at
least 2 years after the recruitment, and the follow-up information was
obtained through clinical visits, medical chart reviews, or telephone
interviews.
2.5. Statistical analysis
The continuous variables were summarized as the mean ± SD or
median with the interquartile range, and categorical variables as pro-
portions. The differences in the categorical variables across the 3 groups
were examined with the use of a Pearson chi-square test’. A one-way
analysis of variance was used to compare the normally distributed var-
iables. Event-free survivals were compared with the use of a log-rank
test, followed by a Bonferroni correction for multiple comparisons. Uni-
variate and multivariate Cox proportional hazard models were used to
determine the predictors of the primary endpoint. Likely parameters
were included as explanatory variables in the models on the basis of a
comparison of the baseline characteristics across the groups. For some
continuous variables included in the models (left ventricular ejection
fraction [16], left ventricular end-systolic volume [16], N-terminal pro-
brain natriuretic peptide [17], Peak VO2 [12,18], and VE/VCO2 slope
[12,18]), the cut-off points were determined according to the current
guidelines or landmark trials. Variables with statistical significance in
the univariate analysis were included in the multivariate models. All
statistical analyses were performed with the use of JMP software ver-
sion 13.0 (SAS Institute, Cary, North Carolina). With Bonferroni correc-
tions, a P value of b0.016 was considered statistically significant.
Otherwise, a P value of b0.05 was considered significant.
3. Results
3.1. Patients
A total of 261 patients were eligible for inclusion. Among them, 17
patients met the exclusion criteria: 12 were unable to exercise, and 3
and 2 had experiencedmyocardial infarction or ischemic stroke, respec-
tively, within 6 weeks before the consideration of inclusion. Another 10
patients were lost to follow-up. Finally, 234 patients were studied. We
found the newest scientific statement-defined EOV in 29 patients
(12.4%, group 1), the OV seen only during exercise in 38 (16.2%, group
2), and no OV pattern in 167 (71.4%, group 3) during CPX testing. The
baseline clinical characteristics and CPX parameters of each patient
group are presented in Table 1.
3.2. Outcomes
We found 10 (34.5%), 4 (10.5%), and 7 (4.2%) cardiac deaths (log-
rank P b 0.001, Fig. 2A) during the follow-up period (mean ± SD, 3.4
± 1.8, 3.7 ± 1.8, 3.6 ± 1.7 years; P= 0.71) in groups 1, 2, and 3 respec-
tively. Worsening heart failure was the most common cause of cardiac
death (8 [80%], 1 [25%], 3 [42.9%]), and unwitnessed sudden death
was the second (2 [20%], 2 [50%], 1[14.3%]). The rate of the composite
outcome differed significantly across the groups (21 [72.4%], 15
[39.5%], and 48 [28.7%]; log-rank P b 0.001, Fig. 2B). With the multiple
pairwise comparisons with Bonferroni corrections, group 1 had the
highest occurrence of the composite outcome of cardiac death and hos-
pitalization forworsening heart failure (vs. group 2; log-rank P=0.015,
vs. group 3, log-rank P b 0.001), however, no significant difference was
found in its occurrence between groups 2 and 3 (log-rank P=0.12).We
found11patientswithOV that persisted throughout a progressive exer-
cise only among patients in group 1, and their incidence of a composite
outcome (81.8%) was similar to that of patients in group 1 who pre-
sented with OV that ceased by the end of exercise (N = 18, 66.7%; P
= 0.67).Please cite this article as: H. Kinoshita, A. Sairaku, N. Morishima, et al., Pr
advanced heart failure u..., International Journal of Cardiology, https://doiIn the multivariate hazard analyses, an N-terminal pro-brain natri-
uretic peptide of N900 pg/mL (P = 0.04) and group 1 (i.e. OV observed
both at rest and during exercise, P = 0.02) were independently associ-
ated with the composite outcome (Table 2).
4. Discussion
The major findings of the present study were two-fold. (i) Patients
with NYHA class III-heart failure who presented with OV both at rest
and during exercise hadmore increased composite outcomes of cardiac
death or hospitalization for worsening heart failure than those with the
OV seen only during exercise or those without any OV. (ii) OV observed
both at rest and during exercise was an independent predictor of the
composite outcome among the NYHA class III-heart failure patients.
According to ourmajor findings, OV seen both at rest and during ex-
ercise versus that observed only during exercise suggests more serious
heart failure. Themechanism is yet hard to explain because no previous
study has focused on the difference between the two OV patterns, and
therefore, little data on it is currently available. Some clue, however,
may come from a study [8], inwhich the cardiac output and intracardiac
pressures were measured invasively during the CPX testing in patientsognostic significance of oscillatory ventilation at rest in patients with
.org/10.1016/j.ijcard.2019.11.098
Fig. 2. Kaplan–Meier estimates comparing the survival free of cardiac death (panel A,
group 1 vs. 2; log-rank P = 0.01, group 1 vs. 3; log-rank P b 0.001, and group 2 vs. 3;
log-rank P = 0.36), and the primary composite outcome of cardiac death or
hospitalization for worsening heart failure (panel B, group 1 vs. 2; log-rank P = 0.015,
group 1 vs. 3; log-rank P b 0.001, and group 2 vs. 3; log-rank P = 0.12) in the 3 patient
groups.
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low cardiac index during exercise rather than the PO2 or PCO2 was the
only single independent predictor of the EOV. They also demonstratedTable 2
Hazard ratio for cardiac death or hospitalization for worsening heart failure (N = 234).
Variables Univariate
Hazard ratio (95% CI)
Age ≥ 75 years 1.23 (0.77–1.92)
Male 1.42 (0.92–2.23)
Diabetes mellitus 0.89 (0.56–1.39)
Atrial fibrillation 1.3 (0.74–2.15)
Left ventricular ejection fraction b 50% 1.71 (1.11–2.62)
Left ventricular end-systolic volume N 43 mL/m2 2.48 (1.59–3.83)
Hemoglobin b 12 g/dL 1.09 (0.83–1.42)
NT pro-BNP N 900 pg/mL 2.45 (1.58–3.86)
Peak VO2 b 14 mL/min/kg 1.88 (1.16–3.19)
VE/VCO2 slope N 34 0.94 (0.59–1.45)
Group 1 3.3 (1.96–5.31)
Group 2 1.22 (0.67–2.07)
CI = confidence interval. The other abbreviations are the same as in Table 1.
Please cite this article as: H. Kinoshita, A. Sairaku, N. Morishima, et al., Pr
advanced heart failure u..., International Journal of Cardiology, https://doia reduced ability to increase the cardiac index during incremental exer-
cise in patients with EOV. On the basis of the findings, they concluded
that an inadequate cardiac index at a given exercise intensity is likely
to lead to EOV. With this concept, the following is possible. Patients
who had an adequate cardiac output to meet the resting oxygen de-
mand did not present with OV during the resting phase in the CPX pro-
tocol. If their cardiac function was not good enough to increase the
stroke volume adequately in response to the increase in the exercise in-
tensity, they developed OV after the start of the incremental exercise.
Patients with more advanced heart failure were unable to preserve an
adequate peripheral organ perfusion even at rest, and thus they had
OV constantly at rest and it was continuously observed or was even en-
hanced during exercise. Of course, this speculation may not solely ex-
plain our major findings because some putative mechanisms
responsible for the EOV other than the reduced cardiac index have
been known, such as an increased chemosensitivity to PaCO2 and
PaO2, or baroreflex impairment [5,19]. For instance, Apostolo et al.
[20] successfully demonstrated that a modification of the
chemosensitivity to carbon dioxide with the use of acetazolamide re-
duced the EOV.
We failed to find any statistical significance in adverse outcomes be-
tween patients with OV seen only during exercise and those without
any OV. That might be apparently different from the finding of previous
studies [7,21] that heart failure patients with EOV had several times
higher mortality compared to those without it. The potential explana-
tions are as follows: (1) It is possible that patients were considered as
having EOV as long as the OV pattern was observed during their incre-
mental exercise, and little attention was paid to whether or not it was
also seen during resting phase in the previous studies [4,21]. On the
other hand, we in the present study checked for the resting OV, which
might have contributed to the identification of potential “benign EOV”.
(2) Unlikemanyprevious studies,we recruited patientswith “heart fail-
ure with preserved ejection fraction (HFpEF)” as well. Patients with
HFpEF generally have a better prognosis than those with “heart failure
with reduced ejection fraction” [16]. That might have contributed to
the statistical insignificance.4.1. Clinical implications
It has long been known that the daytime resting OV also predicts an
increasedmortality among heart failure patients [13]. To the best of our
knowledge, however, the present study is the first to compare the OV at
rest that persists during exercise and the OV observed only during exer-
cise among heart failure patients undergoing CPX. Our major findings
suggest that checking for the resting OV before incremental exercise
during the CPX testing may be helpful in assessing the severity of
heart failure. Further, theymay confirm the validity of the currently rec-
ommended EOV definition.Multivariate
P-value Hazard ratio (95% CI) P-value
0.37
0.12
0.62
0.35
0.02 0.84 (0.46–1.53) 0.58
b0.001 1.72 (0.91–3.33) 0.1
0.53
b0.001 1.72 (1.04–2.89) 0.04
0.001 1.47 (0.88–2.54) 0.15
0.77
b0.001 2.03 (1.12–3.56) 0.02
0.5
ognostic significance of oscillatory ventilation at rest in patients with
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5H. Kinoshita et al. / International Journal of Cardiology xxx (xxxx) xxxA circadian variation in the prevalence of Cheyne-Stokes respiration
has been suggested in patients with advanced heart failure [22,23].
Given that OV is considered to be less severe form of Cheyne-Stokes res-
piration [24], to determine its diurnal pattern in those subjects is a fu-
ture challenge.
4.2. Limitations
We determined the OV visually as in the previous studies [4,5],
which made it difficult to remove the subjectivity entirely. Exertional
OV and sleep apnea often coexist, and the combination has a strong
prognostic value [25]. However, that was not examined in our series.
The present study was a single-center and observational study with a
limited number of participants, and therefore, the statistical power
and its impact on clinical practice are limited.
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